Yossi Carmil: The 19-Year Cellebrite CEO Behind Israel's Digital Forensics Franchise

Yossi Carmil is the Israeli executive who ran Cellebrite (NASDAQ: CLBT) as co-CEO and then sole CEO for 19 years, from January 2005 through December 31, 2024. He joined Cellebrite in January 2004 as the company's fifth employee, serving initially as VP of Sales, and became co-CEO alongside Ron Serber a year later. During his tenure, Cellebrite grew from 18 employees in a small Tel Aviv-area office to more than 1,100 people across a dozen offices worldwide, with roughly 7,000 customers in more than 100 countries, listed on Nasdaq via a 2021 SPAC merger at a ~$2.4 billion pro forma equity value, and reached the first $100 million quarter in Q3 2024 before Carmil announced his retirement.

Before Cellebrite

Carmil holds an MBA from Ludwig-Maximilians University in Munich, Germany, and brings a German-Israeli commercial background. Before Cellebrite, he served as VP of Commercial for Siemens Israel Ltd., Sales Director at Elgad Com Group, and Financial Controller for Bosch in Germany.

He joined Cellebrite in January 2004 as the company's fifth employee, in a VP of Sales role. Cellebrite had been founded in 1999 by Avi Yablonka, Yaron Baratz, and Yuval Aflalo, with Ron Serber joining in 2001. Carmil joined a year before Serber and Carmil were appointed co-CEOs, effective January 1, 2005. That was Cellebrite's fourth calendar year of operation and, arguably, the operating transition point that turned the company from a mobile-carrier retail-store data-transfer vendor into what became the global digital-forensics category leader.

The Category Shift — From Phone-to-Phone Transfer to Digital Forensics

Cellebrite began as a hardware and software vendor selling phone-to-phone data-transfer devices, contact synchronization, and content-transfer tools to wireless-carrier retail stores. In 2007, under Carmil and Serber's co-leadership, Cellebrite established an independent division focused on the mobile-forensics market. That same year, Cellebrite was acquired by FutureDial Incorporated and one of FutureDial's major shareholders — Sun Corporation, based in Nagoya, Japan. Sun Corporation remained Cellebrite's largest shareholder through the Nasdaq listing and beyond.

The mobile-forensics pivot produced the flagship Cellebrite UFED product line — the Universal Forensic Extraction Device that became the industry standard for law-enforcement mobile-device extraction. Over the next fifteen years, the customer base shifted from carriers to police forces, intelligence agencies, and — later — enterprise incident-response and eDiscovery buyers.

The 2019–2021 Growth Capital and Nasdaq Listing

In 2019, Israel Growth Partners (IGP) invested $110 million in Cellebrite — the growth-capital transaction that set up the Nasdaq listing. In January 2020, Cellebrite acquired U.S.-based BlackBag Technologies, expanding into computer forensics alongside mobile.

Ron Serber departed in 2020, and Carmil became sole CEO. In April 2021, Cellebrite announced a merger with the SPAC TWC Tech Holdings II Corporation. The transaction closed in August 2021, listing Cellebrite on Nasdaq under the ticker CLBT at a pro forma implied equity value of approximately $2.4 billion. In hindsight, Carmil later acknowledged the SPAC route — chosen in part to reshape investor perception away from the offensive-cyber category — was slower and produced a different label problem than a traditional IPO would have.

The Controversies

Cellebrite's technology is sold primarily to governments and law-enforcement agencies. Over Carmil's tenure, the misuse of Cellebrite tools by unauthorized parties, or by governments deploying them against journalists and activists, repeatedly produced controversy — including a 2024 Amnesty International report describing Cellebrite technology used against journalists and protesters in Serbia. Cellebrite has periodically withdrawn from specific markets over misuse concerns, including Russia, Hong Kong, and China.

Cellebrite technology was used in the FBI's forensic analysis of the iPhone belonging to the July 2024 suspect in the attempted assassination of Donald Trump — the highest-profile public use case of the company's core product in Carmil's final year as CEO.

Carmil's public framing has consistently been that Cellebrite is a digital-investigation tools company for legally sanctioned use, not an offensive-cyber company — a distinction he has argued was validated by Fidelity and Wellington taking significant post-IPO positions.

The Subscription Transition and the AI Platform

Under Carmil, Cellebrite completed the transition from a perpetual-license model to a subscription business model, launched the AI-driven Case-to-Closure platform, and delivered consistently profitable growth. Q3 2024 revenue grew 27 percent to $107 million — the first $100M+ quarter in company history. Operating profit rose 54 percent to $20 million. Full-year 2024 revenue was tracking to approximately $400 million at a 24 percent growth rate at the point of the CEO transition.

The Retirement and the Post-Carmil Cellebrite

On November 6, 2024, Cellebrite announced Carmil's decision to step down as CEO and board member by December 31, 2024. Executive chairman Thomas E. Hogan — who had joined the board in August 2023 — was named interim CEO pending a formal search. Under Hogan, Cellebrite completed the acquisition of Delray Beach, Florida-based Corellium in June 2025 for approximately $200 million ($150M cash, $20M restricted stock, up to $30M performance-based) — a virtualized-mobile-device-environments platform for security research — and the July 2024 acquisition of Cyber Technology Services (Cytech) in Tysons Corner, Virginia, licensed for federal projects with maximum security clearance.

Why Yossi Carmil Matters to the Israeli Cybersecurity Story

Cellebrite is the commercial franchise of the Israeli mobile-forensics industry — a category adjacent to but structurally distinct from the offensive-cyber cluster (NSO, Paragon, Candiru, Intellexa) that dominates public perception of Israeli cyber exports. Carmil's 19-year tenure was defined by the operational separation of Cellebrite from that offensive-cyber label: a defensive, evidentiary, courtroom-oriented positioning applied consistently through repeated misuse controversies. The Nasdaq listing, the subscription transition, and the exit at a first-$100M-quarter milestone establish Carmil among the most commercially consequential Israeli cyber-adjacent operators of the last two decades.

For adjacent Israeli cyber-and-digital-intelligence founder profiles, see Shlomi Ben Haim on JFrog and Adam Singolda on Taboola.

Frequently Asked Questions

Who is Yossi Carmil?
Israeli executive who ran Cellebrite (NASDAQ: CLBT) as co-CEO and then sole CEO for 19 years, from January 1, 2005 through December 31, 2024. He joined Cellebrite in January 2004 as its fifth employee (VP Sales).

Is Carmil a Cellebrite founder?
No. Cellebrite was founded in 1999 by Avi Yablonka, Yaron Baratz, and Yuval Aflalo. Ron Serber joined in 2001. Carmil joined in 2004 and was appointed co-CEO (with Serber) in 2005.

What did Cellebrite look like when Carmil arrived vs when he left?
18 employees in a small Tel Aviv-area office at his 2004 arrival. 1,100+ employees, a dozen offices worldwide, ~7,000 customers in 100+ countries at his 2024 departure. Nasdaq-listed via 2021 SPAC merger at ~$2.4B pro forma equity value. Q3 2024 the first $100M+ revenue quarter.

Why did Carmil step down?
He publicly framed the departure as retirement after a 19-year CEO tenure at a milestone moment — first $100M quarter, subscription transition complete, AI-driven Case-to-Closure platform launched. Thomas E. Hogan is interim CEO pending a formal successor search.

Who is Cellebrite's largest shareholder?
Sun Corporation of Nagoya, Japan, which acquired Cellebrite in 2007 through its stake in FutureDial. Sun Corporation retained its majority position through the 2021 Nasdaq listing.